|

Long-term Prognosis and Valve Durability of TAVR

RECRUITINGSponsored by Xijing Hospital
Actively Recruiting
SponsorXijing Hospital
Started2016-01
Est. completion2025-12
Eligibility
Age18 Years+
View on ClinicalTrials.gov →

NCT06379386

Summary

This registry aims to evaluate the long-term prognosis and valve durability of transcatheter aortic valve replacement (TAVR) in a real-world setting. Baseline characteristics, procedural data, and clinical outcomes will be collected in a prospective and observational manner.

Eligibility

Age: 18 Years+
Inclusion Criteria:

Patients diagnosed with severe aortic valve regurgitation undergo evaluation by the Heart team and are eligible for TAVR therapy.

2\. Patients who understand the purpose of this study, agree to participate in the trial and sign the informed consent form

* 1\. Patients with aortic stenosis or aortic valve insufficiency who were evaluated by the Heart team and underwent TAVR therapy
* 2\. Patients who understand the purpose of the study, agree to participate in the trial and sign the informed consent form

Exclusion Criteria:

* 1\. Patients who cannot provide informed consent
* 2\. Patients who are participating in other clinical trials

Conditions2

Aortic Valve Stenosis and InsufficiencyHeart Disease

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.